Events

Event When
Credit Suisse London Healthcare Conference

February 28 - March 1, 2023
Barclay's Healthcare Conference

March 14-15, 2023
Jefferies 3rd Pan European Mid Cap Conference

March 28-30, 2023
First Quarter 2023 Financial Results reporting*

April 25, 2023

Annual General Meeting of Shareholders

May 4, 2023

Bank of America Healthcare Conference

 May 9-11, 2023

Jefferies Healthcare Conference

 June 7-9, 2023

Goldman Sachs Global Healthcare Conference

 June 12-15, 2023

Citi European Healthcare Conference

 June 20-21, 2023

J.P. Morgan European Healthcare Conference

 June 22, 2023

Stifel European Healthcare Summit 

 June 29-30, 2023

Half-Year 2023 Financial Results reporting*

 July 25, 2023

Citi BioPharma Conference

 September 6-7, 2023

Morgan Stanley Global Healthcare Conference

 September 11-14, 2023

Bank of America Global Healthcare Conference

 September 13-14, 2023

Baader Investment Conference

 September 18-22, 2023

9-month 2023 Financial Results reporting*

 October 24, 2023

*We will be in a silent period for 10 days ahead of the financial reporting.

Full Year 2022 Financial Results

Idorsia published its full year financial results 2022 on Tuesday February 7, 2023.

Full Year 2022 Financial Results

Idorsia presents at the 41st J.P. Morgan Healthcare Conference

Jean-Paul Clozel, CEO of Idorsia, presented at the 41st J.P. Morgan Healthcare Conference 2023.

We're reaching out for more!

Cenerimod Phase 3 initiation

In December 2022, Idorsia announced that the first patient has entered screening to participate in OPUS, a Phase 3 program to investigate the efficacy and safety of cenerimod, Idorsia’s novel, highly selective S1P1 receptor modulator, as an oral treatment for adult patients with moderate to severe systemic lupus erythematosus.

Cenerimod Phase 3 initiation

Aprocitentan Phase 3 data published in The Lancet

In November 2022, Idorsia announced the publication of “A randomized controlled trial of the dual endothelin antagonist aprocitentan for resistant hypertension” in The Lancet.

Aprocitentan Phase 3 data published in The Lancet

Nine-Month 2022 Financial Results

Idorsia published its financial results for the first nine months of 2022 on Tuesday October 25, 2022.

Nine-Month 2022 Financial Results

Half Year 2022 Financial Results

Idorsia published its half year financial results 2022 on Tuesday
July 26, 2022.

Half Year 2022 Financial Results

Daridorexant Phase 3 data published in The Lancet Neurology

In January 2022, Idorsia announced the publication of "Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials" in The Lancet Neurology.

Daridorexant Phase 3 data published in The Lancet Neurology

Phase 3 initiation: Selatogrel in suspected AMI

In June 2021, Idorsia announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI).

Phase 3 initiation: Selatogrel in suspected AMI

Disclaimer

The information in these investor webcasts was factually accurate at the time of broadcast. These webcasts remain on the Idorsia website for historical purposes only. Idorsia assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these presentations as current or accurate after their publication dates.

Contact

Investor Relations
Hegenheimermattweg 91
4123 Allschwil
Switzerland

Stay informed

Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.

 

"I enjoy working for Idorsia because it is a dynamic and fast moving company."

Lab Head, Pharmacology & Preclinical Development